-
Je něco špatně v tomto záznamu ?
Current views on HIV-1 latency, persistence, and cure
Z. Melkova, P. Shankaran, M. Madlenakova, J. Bodor,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NT14135
MZ0
CEP - Centrální evidence projektů
- MeSH
- biomedicínský výzkum trendy MeSH
- HIV infekce farmakoterapie virologie MeSH
- HIV-1 účinky léků fyziologie MeSH
- latence viru účinky léků MeSH
- látky proti HIV terapeutické užití MeSH
- lidé MeSH
- objevování léků trendy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
HIV-1 infection cannot be cured as it persists in latently infected cells that are targeted neither by the immune system nor by available therapeutic approaches. Consequently, a lifelong therapy suppressing only the actively replicating virus is necessary. The latent reservoir has been defined and characterized in various experimental models and in human patients, allowing research and development of approaches targeting individual steps critical for HIV-1 latency establishment, maintenance, and reactivation. However, additional mechanisms and processes driving the remaining low-level HIV-1 replication in the presence of the suppressive therapy still remain to be identified and targeted. Current approaches toward HIV-1 cure involve namely attempts to reactivate and purge HIV latently infected cells (so-called "shock and kill" strategy), as well as approaches involving gene therapy and/or gene editing and stem cell transplantation aiming at generation of cells resistant to HIV-1. This review summarizes current views and concepts underlying different approaches aiming at functional or sterilizing cure of HIV-1 infection.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17006184
- 003
- CZ-PrNML
- 005
- 20181210100508.0
- 007
- ta
- 008
- 170210s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-016-0474-7 $2 doi
- 035 __
- $a (PubMed)27709447
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mělková, Zora, $u Department of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studnickova 7, 128 00, Prague 2, Czech Republic. zmelk@LF1.cuni.cz. BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec, Průmyslová 595, 252 50, Vestec, Czech Republic. zmelk@LF1.cuni.cz. $d 1965- $7 jo2002103068
- 245 10
- $a Current views on HIV-1 latency, persistence, and cure / $c Z. Melkova, P. Shankaran, M. Madlenakova, J. Bodor,
- 520 9_
- $a HIV-1 infection cannot be cured as it persists in latently infected cells that are targeted neither by the immune system nor by available therapeutic approaches. Consequently, a lifelong therapy suppressing only the actively replicating virus is necessary. The latent reservoir has been defined and characterized in various experimental models and in human patients, allowing research and development of approaches targeting individual steps critical for HIV-1 latency establishment, maintenance, and reactivation. However, additional mechanisms and processes driving the remaining low-level HIV-1 replication in the presence of the suppressive therapy still remain to be identified and targeted. Current approaches toward HIV-1 cure involve namely attempts to reactivate and purge HIV latently infected cells (so-called "shock and kill" strategy), as well as approaches involving gene therapy and/or gene editing and stem cell transplantation aiming at generation of cells resistant to HIV-1. This review summarizes current views and concepts underlying different approaches aiming at functional or sterilizing cure of HIV-1 infection.
- 650 _2
- $a látky proti HIV $x terapeutické užití $7 D019380
- 650 _2
- $a biomedicínský výzkum $x trendy $7 D035843
- 650 _2
- $a objevování léků $x trendy $7 D055808
- 650 _2
- $a HIV infekce $x farmakoterapie $x virologie $7 D015658
- 650 _2
- $a HIV-1 $x účinky léků $x fyziologie $7 D015497
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a latence viru $x účinky léků $7 D017735
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Shankaran, Prakash $u Department of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studnickova 7, 128 00, Prague 2, Czech Republic. $7 _AN066002
- 700 1_
- $a Madlenakova, Michaela $u Department of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studnickova 7, 128 00, Prague 2, Czech Republic. BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec, Průmyslová 595, 252 50, Vestec, Czech Republic.
- 700 1_
- $a Bodor, Josef $u BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec, Průmyslová 595, 252 50, Vestec, Czech Republic. $7 mub2015895829
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 62, č. 1 (2017), s. 73-87
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27709447 $y Pubmed
- 910 __
- $a ABA008 $b online $c sign $y a $z 0
- 990 __
- $a 20170210 $b ABA008
- 991 __
- $a 20181210100629 $b ABA008
- 999 __
- $a ok $b bmc $g 1187885 $s 966831
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 62 $c 1 $d 73-87 $e 20161005 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- GRA __
- $a NT14135 $p MZ0
- LZP __
- $a Pubmed-20170210